GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MeiraGTx Holdings plc
MeiraGTx is a gene therapy company. Its stock price is a venture bet on the success of its complex scientific programs for treating diseases of the eye, salivary glands, and nervous system. The chart reflects the high volatility associated with news from the lab.
Share prices of companies in the market segment - Dna
MeiraGTx Holdings is a gene therapy company developing treatments for inherited and acquired diseases, from eye diseases to Parkinson's. We classify it as part of the DNA Technologies segment, which is at the forefront of medicine. The chart below shows the dynamics of this disruptive, yet high-risk, sector.
Broad Market Index - GURU.Markets
MeiraGTx is a biopharmaceutical company developing gene therapies for a wide range of diseases, from eye diseases to neurodegenerative diseases. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
MGTX - Daily change in the company's share price MeiraGTx Holdings plc
Shares of MeiraGTx, a gene therapy company, are exhibiting the extreme volatility typical of biotech. change_co tracks investors' immediate reactions to the publication of clinical trial data. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
MeiraGTx Holdings plc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with MGTX, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
MeiraGTx is a biopharmaceutical company specializing in gene therapy for the treatment of various diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with MeiraGTx's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MeiraGTx Holdings plc
MeiraGTx is a biotech company developing gene therapy. The company's shares are a bet on a breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Annual dynamics of market capitalization of the market segment - Dna
MeiraGTx Holdings plc is a clinical-stage biotechnology company developing gene therapies for a wide range of diseases. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MeiraGTx is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MeiraGTx Holdings plc
The price of MeiraGTx, a gene therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for eye and neurological diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the biotech sector, particularly in gene therapy. For MeiraGTx, a clinical-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in rare diseases are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MeiraGTx is a clinical-stage gene therapy company for conditions ranging from eye disease to Parkinson's. Its future depends entirely on the success of its trials. The broader market has little impact on MeiraGTx; its shares are driven by scientific news, which can cause explosive gains or losses on any given day, ignoring macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MeiraGTx Holdings plc
MeiraGTx, a gene therapy company, exhibits high volatility. Its weekly stock price is a direct response to news about clinical trials, partnerships with major pharmaceutical companies, and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Dna
MeiraGTx operates in the revolutionary gene therapy sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment, while failure can dampen investor interest. The chart will reveal whether the market perceives MGTX as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, MeiraGTx often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how MGTX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
MGTX - Market capitalization of the company MeiraGTx Holdings plc
MeiraGTx's market capitalization is a reflection of the promise of gene therapy. This biotech company's chart reflects the potential of its developments for treating inherited eye diseases, salivary gland disorders, and Parkinson's disease. Its volatility is directly linked to news of clinical trials and investor confidence in this cutting-edge field of medicine.
MGTX - Share of the company's market capitalization MeiraGTx Holdings plc within the market segment - Dna
MeiraGTx is a clinical-stage gene therapy company focused on diseases of the eye, salivary glands, and central nervous system. Its share of the market capitalization of its innovation segment reflects the potential of its scientific platform. The chart below shows how its weighting changes based on research results and partnerships.
Market capitalization of the market segment - Dna
MeiraGTx Holdings is a company focused on gene therapy for the treatment of inherited diseases of the eye, salivary glands, and nervous system. The chart below shows the market capitalization of this disruptive biotech sector. Its growth reflects a bet on technologies capable of correcting genetic errors.
Market capitalization of all companies included in a broad market index - GURU.Markets
MeiraGTx is a gene therapy company developing treatments for inherited diseases, from eye diseases to neurological disorders. Its market cap is a bet on a revolution in medicine. On a pharmaceutical industry scale, its value represents the hope that we will be able to treat diseases by correcting genetic defects.
Book value capitalization of the company, segment and market as a whole
MGTX - Book value capitalization of the company MeiraGTx Holdings plc
MeiraGTx's book value is capital for gene therapy. It consists of patents for viral vectors for gene delivery, its own state-of-the-art manufacturing facility in London, and cash for clinical trials. The chart below shows how the company built its complex scientific and manufacturing foundation for treating rare diseases.
MGTX - Share of the company's book capitalization MeiraGTx Holdings plc within the market segment - Dna
MeiraGTx Holdings develops gene therapy, operating its own cGMP manufacturing facility and R&D centers. This unique scientific infrastructure is its main tangible asset. The S_BCap_Seg chart shows its share of the physical assets in the innovative gene therapy sector.
Market segment balance sheet capitalization - Dna
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. MeiraGTx, a gene therapy developer, has a more streamlined model. But to produce its complex drugs, it is building its own facilities, becoming more capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
MeiraGTx is a gene therapy company developing "software" for cell treatment. Its assets are not factories, but cutting-edge laboratories and production facilities for creating gene-carrying vectors. The chart below illustrates the material weight behind this highly complex technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MeiraGTx Holdings plc
MeiraGTx's balance sheet is the value of its gene therapy laboratories and production facilities. The market isn't measuring this, but rather the hope inherent in its developments for treating rare genetic diseases. The chart shows how much the company's "bet" on the gene revolution exceeds the value of its current assets.
Market to book capitalization ratio in a market segment - Dna
MeiraGTx Holdings plc is a company developing gene therapy for the treatment of inherited diseases. Its value is based on the potential of its scientific developments. This chart shows how its market valuation, which is a bet on the success of clinical trials, is many times greater than its current tangible assets.
Market to book capitalization ratio for the market as a whole
MeiraGTx is a gene therapy company developing treatments for a variety of diseases, from eye diseases to neurodegenerative diseases. Its value is entirely dependent on the success of its research in the laboratory and clinical trials. This chart shows how the market values its cutting-edge scientific platform, a bet on future medical breakthroughs.
Debts of the company, segment and market as a whole
MGTX - Company debts MeiraGTx Holdings plc
MeiraGTx, a gene therapy company, uses debt and equity financing for its expensive clinical programs. Developing treatments for rare genetic diseases requires massive investments in research and development. This chart shows how the company raises capital to advance its innovative therapies.
Market segment debts - Dna
MeiraGTx is a biotech company developing gene therapy for a variety of diseases, from eye diseases to neurodegenerative disorders. Developing such complex treatments requires significant, long-term investments. This chart shows how the company's debt load reflects its capital requirements for costly clinical trials and construction of manufacturing facilities.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MeiraGTx Holdings plc
MeiraGTx Holdings is a company developing cutting-edge gene therapy. Its research requires massive, long-term investments to achieve commercial results. Debt is a means to sustain success. This chart illustrates the high financial risk inherent in revolutionary science that has yet to prove its commercial value.
Market segment debt to market segment book capitalization - Dna
MeiraGTx, a clinical-stage gene therapy company focused on treating diseases of the eye, salivary glands, and central nervous system, compares its debt load to the overall market capitalization of the entire biotech sector. It shows how the company finances its cutting-edge, yet long-term and risky, research programs.
Debt to book value of all companies in the market
MeiraGTx Holdings is a gene therapy company. Developing such cutting-edge treatments requires massive, long-term investments. This chart of overall market debt provides insight into the availability of capital for biotech companies working at the forefront of science and dependent on external funding for their clinical programs.
P/E of the company, segment and market as a whole
P/E - MeiraGTx Holdings plc
This chart for MeiraGTx Holdings, a gene therapy company, illustrates the complex task of valuing a clinical-stage biotech. There is no profit. Any formal metric reflects not current revenue, but rather investors' faith in the company's scientific platform and its potential to treat a wide range of diseases, from ocular to neurological.
P/E of the market segment - Dna
MeiraGTx Holdings is a gene therapy company developing treatments for a variety of conditions, from inherited eye diseases to neurodegenerative disorders such as Parkinson's. This chart illustrates the average valuation in the biotech sector, where investors are betting on breakthrough scientific platforms with enormous, yet risky, potential.
P/E of the market as a whole
MeiraGTx Holdings is a biotech company developing gene therapy for a variety of diseases, from eye diseases to neurodegenerative disorders. It's a bet on cutting-edge science. This chart shows investors' overall risk appetite. Comparisons show how much MeiraGTx's valuation depends on faith in its unique technology rather than on overall market sentiment in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MeiraGTx Holdings plc
For MeiraGTx Holdings, a gene therapy company, this chart illustrates market expectations for its clinical developments. It reflects investors' faith in scientific breakthroughs and the future commercialization of drugs for the treatment of inherited diseases, which is factored into the company's projected valuation, even though it currently lacks stable profitability.
%20P%2FE%20MeiraGTx%20Holdings%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MeiraGTx-Holdings-plc&v=1772689900878 "Chart of the company's future (projected) P/E MeiraGTx Holdings plc")
Future (projected) P/E of the market segment - Dna
MeiraGTx Holdings is a biotech company developing gene therapies for a variety of diseases, from eye diseases to neurodegenerative diseases. This chart shows expectations for the entire biotech segment. MGTX's position may signal the level of investor confidence in its scientific platform and the potential of its developments to create breakthrough treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772689900886 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
MeiraGTx Holdings is developing gene therapy. For a company in the clinical trial stage, the overall market sentiment reflected in this chart is important for access to capital. Investor appetite for risky biotech projects increases during periods of overall market optimism.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772689900910 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MeiraGTx Holdings plc
MeiraGTx Holdings is a gene therapy company for inherited diseases, ranging from eye diseases to neurological disorders. This chart illustrates the long and risky road to biotech. Periods of losses are due to clinical trial costs, while potential profit explosions depend on the approval of their revolutionary treatments.
Profit of companies in the market segment - Dna
MeiraGTx Holdings is a gene therapy company developing treatments for inherited diseases, from eye diseases to neurological disorders. Profitability in the DNA technology sector is a bet on the future of medicine. This chart reflects investors' belief that the scientific breakthroughs of MGTX and its competitors will one day translate into commercially successful drugs.
Overall market profit
MeiraGTx Holdings, a gene therapy company, addresses fundamental medical problems, making it less vulnerable to short-term economic fluctuations. However, the overall market situation, as shown in the chart, is critical to attracting the massive investments needed to conduct clinical trials and bring revolutionary treatments to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MeiraGTx Holdings plc
MeiraGTx Holdings is a company developing gene therapy for the treatment of inherited diseases. This chart shows its projected future profits, which are entirely dependent on the success of its clinical programs. Analysts and investors view it as an estimate of the likelihood of its scientific developments reaching the market and changing the lives of patients.
%20profit%20of%20the%20company%20MeiraGTx%20Holdings%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MeiraGTx-Holdings-plc&v=1772689901044 "Graph of future (projected) profit of the company MeiraGTx Holdings plc")
Future (predicted) profit of companies in the market segment - Dna
MeiraGTx Holdings is a gene therapy company developing treatments for inherited diseases, from blindness to Parkinson's disease. Its value lies in the potential of its scientific portfolio. This chart shows profit expectations for the biotech sector, reflecting investor confidence in the commercial success of breakthrough genetic technologies in medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772689901085 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
MeiraGTx Holdings is a gene therapy company. Being in clinical development, it doesn't generate stable revenue, and its value depends on scientific breakthroughs and prospects. The overall economic environment, reflected in the forecast, influences the company through investor sentiment: in good times, it's easier to finance such risky projects than in downturns.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772689901093 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MeiraGTx Holdings plc
MeiraGTx Holdings is a company specializing in gene therapy for a variety of diseases, from hereditary blindness to Parkinson's disease. Its revenue at this stage is generated primarily through partnerships with major pharmaceutical companies. This chart shows how the market values these early revenues in the context of the enormous potential of its breakthrough technologies.
P/S market segment - Dna
MeiraGTx Holdings is a biotech company specializing in gene therapy for the treatment of inherited diseases, ranging from eye diseases to neurological disorders. The chart shows the average revenue estimate for the biotech sector. It helps understand how highly investors value the potential of its scientific platform compared to the sector average.
P/S of the market as a whole
MeiraGTx Holdings is a gene therapy company focused on treating inherited diseases. Its value is based almost entirely on the potential of its scientific developments. This chart, showing the average market revenue estimate, vividly illustrates the vast difference between the valuations of mature companies and biotech startups trading on expectations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MeiraGTx Holdings plc
MeiraGTx Holdings is a clinical-stage gene therapy company for the treatment of various diseases. The chart serves as a barometer of market optimism, valuing the company based on the potentially enormous future revenues that could be generated if its innovative therapeutic approaches are successfully approved and brought to market.
%20P%2FS%20MeiraGTx%20Holdings%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MeiraGTx-Holdings-plc&v=1772689901175 "The graph of the company's future (projected) P/S MeiraGTx Holdings plc")
Future (projected) P/S of the market segment - Dna
MeiraGTx Holdings is a company focused on gene therapy for the treatment of inherited diseases, ranging from eye diseases to neurological disorders. The data presented illustrates the average estimated future revenue for biotech companies. This allows one to assess how the market perceives the scientific and commercial potential of MeiraGTx's developments compared to other players.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772689901205 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
MeiraGTx Holdings is a company at the forefront of gene therapy. Its prospects are driven by scientific breakthroughs, not general economic trends. This revenue growth projection has little impact on MeiraGTx's valuation. Investors are focused on the potential of its rare disease treatment platform, which could create enormous value.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772689901325 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MeiraGTx Holdings plc
MeiraGTx is a clinical-stage gene therapy company. Its revenue, shown in the chart, is generated not from sales of finished drugs, but from strategic alliances with pharmaceutical giants. Large but irregular revenues reflect the successful achievement of key milestones in drug research and development.
Sales of companies in the market segment - Dna
MeiraGTx Holdings is a biotech company focused on gene therapy. It develops treatments for a wide range of diseases, from inherited eye diseases to neurodegenerative disorders, by correcting or replacing defective genes. This graph shows the total revenue for the sector, allowing one to assess the commercial progress and potential of the entire gene therapy industry.
Overall market sales
MeiraGTx Holdings is a gene therapy company for a variety of diseases, from eye diseases to neurodegenerative disorders. This chart illustrates economic cycles, but MGTX's business is at the forefront of science. Its market capitalization and success depend on breakthroughs in research and the ability to translate scientific discoveries into real, life-changing treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MeiraGTx Holdings plc
MeiraGTx Holdings is a gene therapy company developing treatments for inherited diseases, ranging from eye diseases to neurological disorders. Its future depends on breakthroughs in clinical trials. This graph reflects the high expectations surrounding the potential success of its innovative treatments.
%20sales%20of%20the%20company%20MeiraGTx%20Holdings%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MeiraGTx-Holdings-plc&v=1772689901476 "Schedule of future (projected) sales of the company MeiraGTx Holdings plc")
Future (projected) sales of companies in the market segment - Dna
MeiraGTx Holdings is a gene therapy company developing treatments for inherited diseases, from eye diseases to neurological disorders. It is at the forefront of medical science. The chart shows projected revenue for the entire DNA technology industry. The company's success depends entirely on the results of clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772689901501 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
MeiraGTx Holdings is involved in gene therapy, developing treatments for hereditary diseases. For such an innovative company, the overall investment climate is crucial, which is indirectly reflected in this chart. Growing business activity and investor confidence ensure an influx of capital into long-term biotech developments, which is critical for funding MGTX's research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772689901562 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MeiraGTx Holdings plc
MeiraGTx Holdings is a gene therapy company focused on treating a wide range of diseases. Being at the forefront of science, it invests heavily in research and development. This chart illustrates the investment required to develop breakthrough treatments that could deliver high returns in the future.
Market segment marginality - Dna
MeiraGTx Holdings is a clinical-stage gene therapy company focused on diseases of the eye, salivary glands, and central nervous system. This chart shows the average profitability in the pharmaceutical industry. The potential of its platform for treating rare diseases could allow the company to achieve profitability significantly above the industry average.
Market marginality as a whole
MeiraGTx Holdings is a company focused on gene therapy for a variety of diseases, from eye diseases to neurodegenerative disorders. Its current financial activity is driven by investments in breakthrough scientific research. This chart clearly illustrates the difference between businesses generating profit today and those working at the cutting edge of science for potentially huge returns in the future.
Employees in the company, segment and market as a whole
Number of employees in the company MeiraGTx Holdings plc
MeiraGTx is a company working in the cutting-edge field of gene therapy. Developing such complex treatments requires a team of highly specialized scientists. The growth in this graph is a clear sign of progress: it means new therapeutic programs are being launched into development, each requiring its own dedicated research team.
Share of the company's employees MeiraGTx Holdings plc within the market segment - Dna
MeiraGTx Holdings is a biotechnology company working at the forefront of gene therapy for the treatment of inherited diseases. Its core asset is its world-class scientists. This chart shows the proportion of unique specialists in this highly complex field that MeiraGTx has, reflecting its scientific prowess and potential for developing revolutionary treatments.
Number of employees in the market segment - Dna
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for a variety of diseases, from eye diseases to neurodegenerative disorders. The increase in the number of scientists and clinical trial specialists on the chart is a leading indicator of progress. This growth in the team indicates that the company's research is moving into more mature stages.
Number of employees in the market as a whole
MeiraGTx Holdings plc develops gene therapy. Its activities are funded by capital raised for research and are not dependent on the current labor market situation, as shown in this chart. The company's success is determined by scientific breakthroughs in the treatment of inherited diseases, which provides value beyond economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings plc is a gene therapy company. Its market capitalization is a measure of its scientific potential and development pipeline. This chart clearly demonstrates how the biotech market values the future. The company's enormous value stems from its small team of scientists, resulting in a very high cost per employee.
%20of%20the%20company%20MeiraGTx%20Holdings%20plc%20(MGTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MeiraGTx-Holdings-plc-MGTX&v=1772689901948 "Chart of market capitalization per employee (in thousands of dollars) of the company MeiraGTx Holdings plc (MGTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
MeiraGTx Holdings is a company specializing in gene therapy for various diseases. Its value lies in its scientific research and clinical trials, led by a highly qualified team. This chart shows how investors assess the long-term potential of its developments per scientist and employee.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772689901972 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
MeiraGTx Holdings is a company focused on gene therapy for treating various diseases. Its main assets are research and development and patents. The chart illustrates the valuation of cutting-edge science. High market capitalization per employee is typical for gene therapy companies, where investors are investing in the technology's potential to transform medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772689901976 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings is a gene therapy company. They operate at the cutting edge of medicine, developing treatments for DNA-based diseases. This chart highlights the high cost of innovation. It likely reflects significant investments (losses) per scientist. This is a measure of how much capital is required per employee to fund breakthrough but expensive R&D.
%20Chart%20MeiraGTx%20Holdings%20plc%20(MGTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MeiraGTx-Holdings-plc-MGTX&v=1772689902008 "Company Profit Per Employee (in thousands of dollars) Chart MeiraGTx Holdings plc (MGTX)")
Profit per employee (in thousands of dollars) in the market segment - Dna
MeiraGTx (MGTX) is an R&D biotech (gene therapy). This chart shows the benchmark for "DNA" (Biotech). The average profit per employee in this sector (R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772689902027 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
MeiraGTx Holdings is a clinical-stage biotech company specializing in gene therapy for a variety of diseases, from eye diseases to neurodegenerative disorders. The company is in the active R&D phase and is not commercially profitable. This chart reflects the current investment (loss) in research per employee working on developing breakthrough treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772689902048 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings is involved in gene therapy. For a biotech company in the clinical trials stage, this chart highlights key monetization points. Increased revenue per employee is typically driven by advance payments from major pharmaceutical partners, reflecting the value of its scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MeiraGTx-Holdings-plc-MGTX&v=1772689902068 "Sales chart per company employee MeiraGTx Holdings plc (MGTX)")
Sales per employee in the market segment - Dna
MeiraGTx (MGTX) is a clinical-stage biotech company specializing in gene therapy. They have several programs in development but no commercial products. This chart doesn't reflect their value. Like other R&D biotechs, their revenue per employee is zero or very low (grants, partnerships), as their focus is on scientific research.
Sales per employee for the market as a whole
MeiraGTx is a biotech company specializing in gene therapy. Their work is at the cutting edge of science. At the current stage of R&D, this metric reflects an investment in the future. It will only begin to grow sharply if their complex therapeutic methods are approved and commercialized, demonstrating the leverage of their intellectual property.
Short shares by company, segment and market as a whole
Shares shorted by company MeiraGTx Holdings plc (MGTX)
MeiraGTx (MGTX) is a biotech company at the forefront of gene therapy. They develop drugs to treat inherited diseases, from eye diseases to neurological disorders. This chart shows the volume of bearish bets. The high skepticism reflects the enormous risks: will the company be able to bring its complex developments to approval and market?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MeiraGTx-Holdings-plc-MGTX&v=1772689902133 "Short Shares Chart for the Company MeiraGTx Holdings plc (MGTX)")
Shares shorted by market segment - Dna
MeiraGTx (MGTX) is a clinical-stage biotech developing gene therapies for a wide range of conditions, from eye diseases to Parkinson's disease. This chart shows the odds against the gene therapy sector. The rising odds against the industry reflect investor skepticism about the safety and efficacy of these complex treatments.
Shares shorted by the overall market
MeiraGTx Holdings (MGTX) is a clinical-stage biotech company specializing in gene therapy for rare diseases (eye, salivary gland). This chart reflects overall market pessimism. When investors are fearful (the indicator rises), they flee en masse from speculative biotechs without profits, fearing that the company will need cash in poor market conditions.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MeiraGTx Holdings plc (MGTX)
MeiraGTx is a biotech company working in gene therapy, focusing on eye and central nervous system diseases. This is a highly speculative field. This chart measures the level of hope. It shows when the stock is "overbought" on encouraging early trial data or "oversold" on news of delays or failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MeiraGTx-Holdings-plc-MGTX&v=1772689902237 "RSI 14 indicator chart for the company's stock MeiraGTx Holdings plc (MGTX)")
RSI 14 Market Segment - Dna
MeiraGTx is a gene therapy company. They develop treatments for a wide range of conditions, from rare eye diseases to Parkinson's, by delivering genes into cells. This chart measures the collective excitement in the gene therapy sector. It helps us understand whether the entire speculative segment is overheated by expectations of a breakthrough.
RSI 14 for the overall market
MeiraGTx (MGTX) is a biotech company. Like everything in its sector, it's critically dependent on this price chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MGTX (MeiraGTx Holdings plc)
MeiraGTx is a biotech company developing gene therapies for a wide range of diseases, from eye diseases to neurodegenerative diseases. This chart shows the average analyst forecast. Their targets are based on clinical data, potential partnerships (like with J&J), and the long-term value of their technology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MGTX-MeiraGTx-Holdings-plc&v=1772689902469 "A chart showing analyst consensus forecasts for the expected stock price. MGTX (MeiraGTx Holdings plc)")
The difference between the consensus estimate and the actual stock price MGTX (MeiraGTx Holdings plc)
MeiraGTx is a biotech company focused on gene therapy. Their R&D pipeline is aimed at treating severe eye diseases, salivary gland diseases, and neurological disorders such as Parkinson's disease. This chart reflects analysts' speculative expectations for their clinical data and technology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MGTX-MeiraGTx-Holdings-plc&v=1772689902490 "A chart showing the difference between the consensus forecast and the actual stock price. MGTX (MeiraGTx Holdings plc)")
Analyst consensus forecast for stock prices by market segment - Dna
MeiraGTx is a biotech company developing gene therapies for the treatment of inherited eye, salivary gland, and neurological disorders. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe this complex R&D platform will be commercially successful.
Analysts' consensus forecast for the overall market share price
MeiraGTx Holdings is a clinical-stage biotech company specializing in gene therapy. They are developing treatments for ocular, neurological, and salivary diseases. This chart shows the overall risk appetite. For MeiraGTx, which operates at the forefront of science, overall market optimism is critical to attracting the capital needed to fund lengthy and expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MeiraGTx Holdings plc
MeiraGTx is a clinical-stage biotech company specializing in gene therapy. They develop drugs to treat rare inherited diseases, targeting the eye (retina), salivary glands, and central nervous system. This graph is a pure assessment of their R&D platform. Its dynamics depend entirely on their progress in clinical trials and confidence in their gene delivery technology.
AKIMA Market Segment Index - Dna
MeiraGTx (MGTX) is a clinical-stage biotech and a pioneer in gene therapy. The company develops (AAV) drugs for the treatment of rare diseases of the eye, salivary glands, and central nervous system. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (R&D platform) model (MGTX) differentiate it from the average pharma company?
The AKIM Index for the overall market
MeiraGTx is a vertically integrated gene therapy company developing treatments for eye and neurodegenerative diseases. This chart, which reflects the market average, is a risk appetite indicator. It provides a macro backdrop that is critical for assessing how the market perceives the company's clinical risks.
